Search Protocols under revision. Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologyProtocol groupRare Diseases (ped.)DiseaseNeurofibromatosisSubgroupPlexiform Neurofibromatype 1ICD10Q85.0MeSHNeurofibroma, PlexiformNeurofibromatosis 1SequenceAntineoplastic therapySubstanceSelumetinibSubstanceSelumetinibSubstanceSelumetinibSubstanceSelumetinibNo. Substances1 RadiotherapySupportive therapySubstanceSubstanceSubstanceSubstanceNo. SubstancesProtocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlCardiotoxicityConstipationDiarrheaEmetogenicityHypocalcemiaIncrease AminotransferasesIncrease Creatinine PhosphokinaseMucositisNail ChangesNeutropeniaPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µl only studiesPublicationAuthorGross AMDiseaseNeurofibromatose Typ 1, Plexiforme Neurofibrome nicht operabel, <18 JahreOriginNational Institutes of Health, BethesdaProtocols in Revision 1 protocol foundSelumetinib 25, neurofibromatosis (PID2226 V1.0)
